Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Acceptability Study of Oral Emtricitabine/Tenofovir Alafenamide (F/TAF) vs Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for the Prevention of HIV Acquisition in Adolescent Girls and Young Women (AGYW)

NCT05458765 is registered in ClinicalTrials.gov with Eastern Virginia Medical School as lead sponsor.

NCT NCT05458765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05458765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Acceptability Study of Oral Emtricitabine/Tenofovir Alafenamide (F/TAF) vs Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for the Prevention of HIV Acquisition in Adolescent Girls and Young Women (AGYW)
Lead sponsor
Eastern Virginia Medical School
Phase
Phase 2
Overall status
Completed
Start date
June 21, 2022
Completion date
July 25, 2024
Enrollment
330 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acceptability of health care, adherence, medication